Our team is led by seasoned industry veterans who are dedicated to improving the lives of patients.
Chief Executive Officer
Mr. Knickerbocker has served as the Chief Executive Officer of Five Prime since January 2018. Prior to this, he served as Chief Operating Officer since September 2016 and as a member of the Board of Directors since October 2013. He previously served as the Company’s Chief Business Officer from April 2012 to September 2016, as Executive Vice President from August 2015 to September 2016, and as Senior Vice President from April 2012 to August 2015. Prior to that, he was Vice President, Business Development from September 2009 to April 2012. From 2001 to September 2009, Mr. Knickerbocker served at Genentech in positions of increasing responsibility most recently as Senior Director, Business Development from 2005 to September 2009. Prior to 2001, Mr. Knickerbocker served as Director of Commercial Development at ALZA, a pharmaceutical company acquired by Johnson & Johnson, as Senior Manager, Corporate Development at Amgen, and as a scientist at Bristol-Myers Squibb. Mr. Knickerbocker received an A.B. in Biology from Washington University in St. Louis and an M.B.A. from the University of Michigan.
Chief Strategy Officer and Secretary
Mr. Sarena has served as our Chief Strategy Officer since September 2016 and as Secretary since December 2010. He also served as our Executive Vice President from August 2015 to September 2016, General Counsel from December 2010 to September 2016, Senior Vice President from January 2013 to August 2015 and as Vice President from December 2010 to January 2013. From December 2008 to July 2010, Mr. Sarena served as Vice President, General Counsel and Secretary of Facet Biotech Corporation, a public biotechnology company that was spun off from PDL BioPharma, Inc. in December 2008 and that was later acquired by Abbott Laboratories in April 2010. From April 2006 to December 2008, Mr. Sarena served at PDL BioPharma, Inc. in positions of increasing responsibility, most recently as Vice President, General Counsel and Secretary from June 2008 to December 2008. Prior to April 2006, Mr. Sarena served as an associate at Bingham McCutchen LLP where he represented public and private life science and high tech clients primarily in merger and acquisition transactions, corporate and securities law matters and equity financing transactions. Mr. Sarena received a B.S. in Finance from San Francisco State University and a J.D. from the University of California, Berkeley.
Helen Collins, M.D.
Senior Vice President and Chief Medical Officer
Dr. Collins has served as our Senior Vice President and Chief Medical Officer since March 2017. She also served as our Vice President of Clinical Development from June 2016 to March 2017. From June 2013 to June 2016, Dr. Collins held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Program and Clinical Lead for Gilead’s GS-5829 (BET inhibitor) and GS-4059 (BTK inhibitor) programs. From November 2009 to May 2013, Dr. Collins held positions of increasing responsibility at Amgen Inc., most recently as Global Lead, Oncology Biosimiliars. Prior to joining Amgen, Dr. Collins practiced as a medical oncologist and hematologist for 12 years at Redwood Regional Medical Group (RRMG) and served as President of RRMG from 2006 to 2009. In 2005, Dr. Collins co-founded the non-profit North Bay Cancer Alliance (NBCA), whose mission is to increase local access to education and cancer care in counties in the northern San Francisco Bay Area. Dr. Collins received an A.B. in Chemistry from Bryn Mawr College and an M.D. from Johns Hopkins University School of Medicine. Dr. Collins completed her residency in internal medicine at Johns Hopkins Hospital and completed her fellowship at Stanford University School of Medicine, where she concentrated in gastrointestinal cancer. Dr. Collins is board certified in both oncology and internal medicine.
Nallakkan S. Arvindan, Ph.D.
Senior Vice President, Strategic Technology Operations
Dr. Arvindan has served as our Senior Vice President, Strategic Technology Operations since February 2018 and served in positions of increasing responsibility, most recently as our Vice President, Strategic Technology Operations, from February 2012 to February 2018, and from December 2009 to August 2011. From September 2011 to February 2012, Dr. Arvindan served as Senior Technology-Engineering Manager, Strategic Technical Operations at IDEXX Laboratories, Inc. From July 2003 to December 2009, Dr. Arvindan served in positions of increasing responsibility, most recently as Engineering Manager, at Symyx Technologies, Inc, which was acquired by Accelrys, Inc. in 2010. Dr. Arvindan received an M.B.A. from the University of California, Berkeley, a Ph.D. in Chemical Engineering and Nanotechnology from the University of Washington, Seattle, and a B.Tech in Chemical and Electrochemical Engineering from the Central Electro-Chemical Research Institute in Karaikudi, India.
Executive Vice President and Chief Financial Officer
Mr. Smith has served as our Executive Vice President and Chief Financial Officer since November 2018. From May 2012 until its acquisition by Thermo Fisher Scientific Inc. in March 2018, Mr. Smith served as Chief Operating Officer of IntegenX, Inc., a biotechnology company. From December 2006 to July 2011, Mr. Smith served as Executive Vice President and Chief Financial Officer of Thoratec Corporation, a public medical device company that was later acquired by St. Jude Medical. From 1999 until its acquisition by Novartis International AG in 2006, Mr. Smith served in positions of increasing responsibility at Chiron Corporation, a public biotechnology company, most recently as Vice President and Chief Financial Officer. From 1997 until its acquisition by Corixa Corporation in 1999, Mr. Smith served as Vice President, Finance and Chief Financial Officer of Anergen, Inc., a public biotechnology company. Prior to Anergen, Mr. Smith served in various roles at Genentech, Inc., IBM Corporation and Syntex Corporation. Mr. Smith currently serves as a member of the board of directors and chair of the audit and finance committees of Codexis, Inc., a public biotechnology company. Mr. Smith previously served as a member of the board of directors of OncoGenex Pharmaceuticals Inc., a public biotechnology company. Mr. Smith received an M.B.A., Finance from Golden Gate University and a B.A. in Economics and History from Willamette University.